Enhancing the delivery of resveratrol in humans: If low bioavailability is the problem, what is the solution?

Molecules

Volumn 19, Issue 11, 2014, Pages 17154-17172

  Smoliga, James M ^a   Blanchard, Otis ^b  

^a HIGH POINT UNIVERSITY   (United States)

^b Wilmore Labs LLC   (United States)

Author keywords

Nutraceutical; Pharmacodynamics; Pharmacokinetics; Phytochemical; Red wine; SIRT1; Sirtuins; Stilbene

Indexed keywords

RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; BIOAVAILABILITY; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; NANOTECHNOLOGY; PROCEDURES;

ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; HUMANS; NANOTECHNOLOGY; STILBENES;

EID: 84913556203     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191117154     Document Type: Review

References (112)

1. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493-506.
2. Blagosklonny, M.V. Aging is not programmed: Genetic pseudo-program is a shadow of developmental growth. Cell Cycle 2013, 12, 3736-3742.
3. Teschendorff, A.E. Epigenetic aging: Insights from network biology. Aging 2013, 5, 719-720.
4. Soares, J.P.; Cortinhas, A.; Bento, T.; Leitao, J.C.; Collins, A.R.; Gaivao, I.; Mota, M.P. Aging and DNA damage in humans: A meta-analysis study. Aging 2014, 6, 432-439.
5. Stauch, K.L.; Purnell, P.R.; Fox, H.S. Aging synaptic mitochondria exhibit dynamic proteomic changes while maintaining bioenergetic function. Aging 2014, 6, 320-334.
6. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337-342.
7. Miller, R.A.; Harrison, D.E.; Astle, C.M.; Baur, J.A.; Boyd, A.R.; de Cabo, R.; Fernandez, E.; Flurkey, K.; Javors, M.A.; Nelson, J.F.; et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. Ser. A-Biol. Sci. Med. 2011, 66, 191-201.
8. Poulsen, M.M.; Vestergaard, P.F.; Clasen, B.F.; Radko, Y.; Christensen, L.P.; Stodkilde-Jorgensen, H.; Moller, N.; Jessen, N.; Pedersen, S.B.; Jorgensen, J.O. High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. Diabetes 2012, 62, 1186-1195.
9. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
10. Olesen, J.; Gliemann, L.; Bienso, R.; Schmidt, J.; Hellsten, Y.; Pilegaard, H. Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men. J. Physiol. 2014, 592, 1873-1886.
11. Smoliga, J.M.; Colombo, E.S.; Campen, M.J. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging 2013, 5, 495-506.
12. Park, S.J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A.L.; et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148, 421-433.
13. Gertz, M.; Nguyen, G.T.; Fischer, F.; Suenkel, B.; Schlicker, C.; Franzel, B.; Tomaschewski, J.; Aladini, F.; Becker, C.; Wolters, D.; et al. A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One 2012, 7, e49761.
14. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.-L.; et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
15. Hubbard, B.P.; Gomes, A.P.; Dai, H.; Li, J.; Case, A.W.; Considine, T.; Riera, T.V.; Lee, J.E.; E, S.Y.; Lamming, D.W.; et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339, 1216-1219.
16. Price, N.L.; Gomes, A.P.; Ling, A.J.; Duarte, F.V.; Martin-Montalvo, A.; North, B.J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J.S.; et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15, 675-690.
17. Baur, J.A.; Ungvari, Z.; Minor, R.K.; le Couteur, D.G.; de Cabo, R. Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Discov. 2012, 11, 443-461.
18. Smith, J.J.; Kenney, R.D.; Gagne, D.J.; Frushour, B.P.; Ladd, W.; Galonek, H.L.; Israelian, K.; Song, J.; Razvadauskaite, G.; Lynch, A.V.; et al. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Boil. 2009, 3, 31.
19. Wenzel, E.; Somoza, V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49, 472-481.
20. Vitaglione, P.; Sforza, S.; Galaverna, G.; Ghidini, C.; Caporaso, N.; Vescovi, P.P.; Fogliano, V.; Marchelli, R. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 2005, 49, 495-504.
21. Gescher, A.J.; Steward, W.P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol. Biomark. Prev. 2003, 12, 953-957.
22. Smoliga, J.M.; Baur, J.A.; Hausenblas, H.A. Resveratrol and health-a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55, 1129-1141.
23. Brown, V.A.; Patel, K.R.; Viskaduraki, M.; Crowell, J.A.; Perloff, M.; Booth, T.D.; Vasilinin, G.; Sen, A.; Schinas, A.M.; Piccirilli, G.; et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis. Cancer Res. 2010, 70, 9003-9011.
24. Ghanim, H.; Sia, C.L.; Korzeniewski, K.; Lohano, T.; Abuaysheh, S.; Marumganti, A.; Chaudhuri, A.; Dandona, P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J. Clin. Endocrinol. Metab. 2011, 96, 1409-1414.
25. Agarwal, B.; Campen, M.J.; Channell, M.M.; Wherry, S.J.; Varamini, B.; Davis, J.G.; Baur, J.A.; Smoliga, J.M. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol. 2013, 166, 246-248.
26. Hausenblas, H.A.; Schoulda, J.A.; Smoliga, J.M. Resveratrol treatment as an adjunct to pharmacological management in Type 2 diabetes mellitus-systematic review and meta-analysis. Mol. Nutr. Food Res. 2014, doi:10.1002/mnfr.201400173.
27. Elliott, P.; Walpole, S.; Morelli, L.; Lambert, P.; Lunsmann, W.; Westphal, C.; Lavu, S. Resveratrol /SRT-501. Drugs Future 2009, 34, 291-295.
28. Kennedy, D.O.; Wightman, E.L.; Reay, J.L.; Lietz, G.; Okello, E.J.; Wilde, A.; Haskell, C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91, 1590-1597.
29. Wong, R.H.; Berry, N.M.; Coates, A.M.; Buckley, J.D.; Bryan, J.; Kunz, I.; Howe, P.R. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J. Hypertens. 2013, 31, 1819-1827.
30. Wong, R.H.; Howe, P.R.; Buckley, J.D.; Coates, A.M.; Kunz, I.; Berry, N.M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 851-856.
31. Smoliga, J.M.; Blanchard, O.L. Recent data do not provide evidence that resveratrol causes "mainly negative" or "adverse" effects on exercise training in humans. J. Physiol. 2013, 591, 5251-5252.
32. Nieuwenhuis, S.; Forstmann, B.U.; Wagenmakers, E.J. Erroneous analyses of interactions in neuroscience: A problem of significance. Nat. Neurosci. 2011, 14, 1105-1107.
33. Wellek, S.; Blettner, M. On the proper use of the crossover design in clinical trials: Part 18 of a series on evaluation of scientific publications. Deutsch. Arztebl. Int. 2012, 109, 276-281.
34. Smoliga, J.M.; Vang, O.; Baur, J.A. Challenges of Translating Basic Research into Therapeutics: Resveratrol as an Example. J. Gerontol. Ser. 2011, 67,158-167.
35. Thompson, A.M.; Martin, K.A.; Rzucidlo, E.M. Resveratrol induces vascular smooth muscle cell differentiation through stimulation of SirT1 and AMPK. PLoS One 2014, 9, e85495.
36. Szende, B.; Tyihak, E.; Kiraly-Veghely, Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp. Mol. Med. 2000, 32, 88-92.
37. Jagdeo, J.; Adams, L.; Lev-Tov, H.; Sieminska, J.; Michl, J.; Brody, N. Dose-dependent antioxidant function of resveratrol demonstrated via modulation of reactive oxygen species in normal human skin fibroblasts in vitro. J. Drugs Dermatol. 2010, 9, 1523-1526.
38. Stocco, B.; Toledo, K.; Salvador, M.; Paulo, M.; Koyama, N.; Torqueti Toloi, M.R. Dose-dependent effect of resveratrol on bladder cancer cells: Chemoprevention and oxidative stress. Maturitas 2012, 72, 72-78.
39. Peltz, L.; Gomez, J.; Marquez, M.; Alencastro, F.; Atashpanjeh, N.; Quang, T.; Bach, T.; Zhao, Y. Resveratrol exerts dosage and duration dependent effect on human mesenchymal stem cell development. PLoS One 2012, 7, e37162.
40. Wallerath, T.; Deckert, G.; Ternes, T.; Anderson, H.; Li, H.; Witte, K.; Forstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002, 106, 1652-1658.
41. Walle, T.; Walle, U.K.; Sedmera, D.; Klausner, M. Benzo[A]pyrene-induced oral carcinogenesis and chemoprevention: Studies in bioengineered human tissue. Drug Metab. Dispos. 2006, 34, 346-50.
42. Planas, J.M.; Alfaras, I.; Colom, H.; Juan, M.E. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Arch. Biochem. Biophys. 2012, 527, 67-73.
43. Kuhnle, G.; Spencer, J.P.; Chowrimootoo, G.; Schroeter, H.; Debnam, E.S.; Srai, S.K.; Rice-Evans, C.; Hahn, U. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Commun. 2000, 272, 212-217.
44. Miksits, M.; Maier-Salamon, A.; Aust, S.; Thalhammer, T.; Reznicek, G.; Kunert, O.; Haslinger, E.; Szekeres, T.; Jaeger, W. Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 2005, 35, 1101-1119.
45. Boocock, D.J.; Faust, G.E.S.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemoprotective agent. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1246-1252.
46. Amiot, M.J.; Romier, B.; Dao, T.M.; Fanciullino, R.; Ciccolini, J.; Burcelin, R.; Pechere, L.; Emond, C.; Savouret, J.F.; Seree, E. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 2013, 95, 1233-1238.
47. Almeida, L.; Vaz-da-Silva, M.; Falcao, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.-F.; Nunes, T.; Wright, L.; et al. Pharmacokinetic and safety profile of transresveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009, 53, S7-S15.
48. Fan, J.; de Lannoy, I.A. Pharmacokinetics. Biochem. Pharmacol. 2014, 87, 93-120.
49. Howells, L.M.; Moiseeva, E.P.; Neal, C.P.; Foreman, B.E.; Andreadi, C.K.; Sun, Y.Y.; Hudson, E.A.; Manson, M.M. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol. Sin. 2007, 28, 1274-1304.
50. Francioso, A.; Mastromarino, P.; Masci, A.; d'Erme, M.; Mosca, L. Chemistry, stability and bioavailability of resveratrol. Med. Chem. 2014, 10, 237-245.
51. Das, S.; Lin, H.S.; Ho, P.C.; Ng, K.Y. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharmaceut. Res. 2008, 25, 2593-2600.
52. Jose, S.; Anju, S.S.; Cinu, T.A.; Aleykutty, N.A.; Thomas, S.; Souto, E.B. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int. J. Pharmaceut. 2014, 474, 6-13.
53. Amri, A.; Chaumeil, J.C.; Sfar, S.; Charrueau, C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Control. Release 2012, 158, 182-193.
54. Howells, L.M.; Berry, D.P.; Elliott, P.J.; Jacobson, E.W.; Hoffmann, E.; Hegarty, B.; Brown, K.; Steward, W.P.; Gescher, A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011, 4, 1419-1425.
55. Kenealey, J.D.; Subramanian, L.; van Ginkel, P.R.; Darjatmoko, S.; Lindstrom, M.J.; Somoza, V.; Ghosh, S.K.; Song, Z.; Hsung, R.P.; Kwon, G.S.; et al. Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells. J. Agric. Food Chem. 2011, 59, 4979-4986.
56. Goldberg, D.M.; Yan, J.; Soleas, G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 2003, 36, 79-87.
57. La Porte, C.; Voduc, N.; Zhang, G.; Seguin, I.; Tardiff, D.; Singhal, N.; Cameron, D.W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharmacokinet. 2010, 49, 449-454.
58. Vaz-da-Silva, M.; Loureiro, A.I.; Falcao, A.; Nunes, T.; Rocha, J.F.; Fernandes-Lopes, C.; Soares, E.; Wright, L.; Almeida, L.; Soares-da-Silva, P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int. J. Clin. Pharmacol. Ther. 2008, 46, 564-570.
59. Johnson, J.J.; Nihal, M.; Siddiqui, I.A.; Scarlett, C.O.; Bailey, H.H.; Mukhtar, H.; Ahmad, N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 2011, 55, 1169-1176.
60. Tak, J.K.; Lee, J.H.; Park, J.W. Resveratrol and piperine enhance radiosensitivity of tumor cells. BMB Rep. 2012, 45, 242-246.
61. Huang, W.; Chen, Z.; Wang, Q.; Lin, M.; Wu, S.; Yan, Q.; Wu, F.; Yu, X.; Xie, X.; Li, G.; et al. Piperine potentiates the antidepressant-like effect of trans-resveratrol: Involvement of monoaminergic system. Metab. Brain Dis. 2013, 28, 585-595.
62. Wightman, E.L.; Reay, J.L.; Haskell, C.F.; Williamson, G.; Dew, T.P.; Kennedy, D.O. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: A randomised, double-blind, placebo-controlled, cross-over investigation. Br. J. Nutr. 2014, 112, 203-213.
63. Volak, L.P.; Ghirmai, S.; Cashman, J.R.; Court, M.H. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab. Dispos. 2008, 36, 1594-1605.
64. DeSanti, C.; Pietrabissa, A.; Mosca, F.; Pacifici, G.M. Glucuronidation of resveratrol, a natural compound present in wine, in the human liver. Xenobiotica 2000, 30, 1047-1054.
65. DeSanti, C.; Pietrabissa, A.; Spisni, R.; Mosca, F.; Pacifici, G.M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 2000, 30, 857-866.
66. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S-242S.
67. Biasutto, L.; Zoratti, M. Prodrugs of quercetin and resveratrol: A strategy under development. Curr. Drug Metab. 2014, 15, 77-95.
68. Liang, L.; Liu, X.; Wang, Q.; Cheng, S.; Zhang, S.; Zhang, M. Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. Phytomedicine 2013, 20, 558-563.
69. Koide, K.; Osman, S.; Garner, A.L.; Song, F.; Dixon, T.; Greenberger, J.S.; Epperly, M.W. The Use of 3,5,4'-Tri-O-acetylresveratrol as a Potential Pro-drug for Resveratrol Protects Mice from gamma-Irradiation-Induced Death. ACS Med. Chem. Lett. 2011, 2, 270-274.
70. Oskarsson, A.; Spatafora, C.; Tringali, C.; Andersson, A.O. Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs. Prostate 2014, 74, 839-851.
71. Popat, R.; Plesner, T.; Davies, F.; Cook, G.; Cook, M.; Elliott, P.; Jacobson, E.; Gumbleton, T.; Oakervee, H.; Cavenagh, J. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haematol. 2013, 160, 714-717.
72. Colom, H.; Alfaras, I.; Maijo, M.; Juan, M.E.; Planas, J.M. Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm. Res. 2011, 28, 1606-1621.
73. Juan, M.E.; Maijo, M.; Planas, J.M. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 2010, 51, 391-398.
74. Gordish, K.L.; Beierwaltes, W.H. Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am. J. Physiol.-Ren. Physiol. 2014, 306, F542-F550.
75. Karaoglan, A.; Akdemir, O.; Barut, S.; Kokturk, S.; Uzun, H.; Tasyurekli, M.; Colak, A. The effects of resveratrol on vasospasm after experimental subarachnoidal hemorrhage in rats. Surg. Neurol. 2008, 70, 337-343.
76. Shin, J.A.; Lee, H.; Lim, Y.K.; Koh, Y.; Choi, J.H.; Park, E.M. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J. Neuroimmunol. 2010, 227, 93-100.
77. Ansari, K.A.; Vavia, P.R.; Trotta, F.; Cavalli, R. Cyclodextrin-Based Nanosponges for Delivery of Resveratrol: In Vitro Characterisation, Stability, Cytotoxicity and Permeation Study. AAPS PharmSciTech 2011, 12, 279-286.
78. Blanchard, O.L.; Friesenhahn, G.; Javors, M.A.; Smoliga, J.M. Development of a lozenge for oral transmucosal delivery of trans-resveratrol in humans: Proof of concept. PLoS One 2014, 9, e90131.
79. Madhav, N.V.; Shakya, A.K.; Shakya, P.; Singh, K. Orotransmucosal drug delivery systems: A review. J. Control. Release 2009, 140, 2-11.
80. Zhang, H.; Zhang, J.; Streisand, J.B. Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 2002, 41, 661-680.
81. Streisand, J.B.; Jaarsma, R.L.; Gay, M.A.; Badger, M.J.; Maland, L.; Nordbrock, E.; Stanley, T.H. Oral transmucosal etomidate in volunteers. Anesthesiology 1998, 88, 89-95.
82. Yeo, S.C.; Ho, P.C.; Lin, H.S. Pharmacokinetics of pterostilbene in Sprague-Dawley rats: The impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol. Nutr. Food Res. 2013, 57, 1015-1025.
83. Marier, J.F.; Vachon, P.; Gritsas, A.; Zhang, J.; Moreau, J.P.; Ducharme, M.P. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 2002, 302, 369-373.
84. Hamid, H.; Coltart, J. "Miracle stents"-A future without restenosis. McGill J. Med. 2007, 10, 105-111.
85. Kleinedler, J.J.; Foley, J.D.; Orchard, E.A.; Dugas, T.R. Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization. J. Control. Release 2012, 159, 27-33.
86. Yurdagul, A., Jr.; Kleinedler, J.J.; McInnis, M.C.; Khandelwal, A.R.; Spence, A.L.; Orr, A.W.; Dugas, T.R. Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-alpha-dependent pathway. Am. J. Physiol. 2014, 306, H797-H806.
87. Khandelwal, A.R.; Hebert, V.Y.; Dugas, T.R. Essential role of ER-alpha-dependent NO production in resveratrol-mediated inhibition of restenosis. Am. J. Physiol. 2010, 299, H1451-H1458.
88. Sessa, M.; Tsao, R.; Liu, R.; Ferrari, G.; Donsi, F. Evaluation of the stability and antioxidant activity of nanoencapsulated resveratrol during in vitro digestion. J. Agric. Food Chem. 2011, 59, 12352-12360.
89. Frozza, R.L.; Bernardi, A.; Paese, K.; Hoppe, J.B.; da Silva, T.; Battastini, A.M.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol. 2010, 6, 694-703.
90. Guo, L.; Peng, Y.; Yao, J.; Sui, L.; Gu, A.; Wang, J. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother. Radiopharm. 2010, 25, 471-477.
91. Lin, S.P.; Chu, P.M.; Tsai, S.Y.; Wu, M.H.; Hou, Y.C. Pharmacokinetics and tissue distribution of resveratrol, emodin and their metabolites after intake of Polygonum cuspidatum in rats. J. Ethnopharmacol. 2012, 144, 671-676.
92. Lou, B.S.; Wu, P.S.; Hou, C.W.; Cheng, F.Y.; Chen, J.K. Simultaneous quantification of trans-resveratrol and its sulfate and glucuronide metabolites in rat tissues by stable isotope-dilution UPLC-MS/MS analysis. J. Pharmaceut. Biomed. Anal. 2014, 94, 99-105.
93. Wang, D.; Xu, Y.; Liu, W. Tissue distribution and excretion of resveratrol in rat after oral administration of Polygonum cuspidatum extract (PCE). Phytomedicine 2008, 15, 859-866.
94. Singh, G.; Pai, R.S. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS. J. Control. Release 2014, 194, 178-188.
95. Wang, S.; Su, R.; Nie, S.; Sun, M.; Zhang, J.; Wu, D.; Moustaid-Moussa, N. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem. 2014, 25, 363-376.
96. Pangeni, R.; Sahni, J.K.; Ali, J.; Sharma, S.; Baboota, S. Resveratrol: Review on therapeutic potential and recent advances in drug delivery. Expert Opin. Drug Deliv. 2014, 11, 1285-1298.
97. Hoshino, J.; Park, E.J.; Kondratyuk, T.P.; Marler, L.; Pezzuto, J.M.; van Breemen, R.B.; Mo, S.; Li, Y.; Cushman, M. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 2010, 53, 5033-5043.
98. Calamini, B.; Ratia, K.; Malkowski, M.G.; Cuendet, M.; Pezzuto, J.M.; Santarsiero, B.D.; Mesecar, A.D. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 2010, 429, 273-282.
99. Patel, K.R.; Andreadi, C.; Britton, R.G.; Horner-Glister, E.; Karmokar, A.; Sale, S.; Brown, V.A.; Brenner, D.E.; Singh, R.; Steward, W.P.; et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3005870.
100. Lasa, A.; Churruca, I.; Eseberri, I.; Andres-Lacueva, C.; Portillo, M.P. Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol. Nutr. Food Res. 2012, 56, 1559-1568.
101. Eseberri, I.; Lasa, A.; Churruca, I.; Portillo, M.P. Resveratrol Metabolites Modify Adipokine Expression and Secretion in 3T3-L1 Pre-Adipocytes and Mature Adipocytes. PLoS One 2013, 8, e63918.
102. Lu, D.L.; Ding, D.J.; Yan, W.J.; Li, R.R.; Dai, F.; Wang, Q.; Yu, S.S.; Li, Y.; Jin, X.L.; Zhou, B. Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. ChemBioChem 2013, 14, 1094-1104.
103. Miksits, M.; Wlcek, K.; Svoboda, M.; Thalhammer, T.; Ellinger, I.; Stefanzl, G.; Falany, C.N.; Szekeres, T.; Jaeger, W. Expression of sulfotransferases and sulfatases in human breast cancer: Impact on resveratrol metabolism. Cancer Lett. 2010, 289, 237-245.
104. Sinclair, D.A.; Guarente, L. Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol. 2014, 54, 363-380.
105. Kleinedler, J.J.; Pjescic, I.; Bullock, K.K.; Khaliq, A.; Foley, J.D.; Dugas, T.R. Arterial pharmacokinetics of red wine polyphenols: Implications for novel endovascular therapies targeting restenosis. J. Pharm. Sci. 2012, 101, 1917-1931.
106. Forstermann, U.; Munzel, T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 2006, 113, 1708-1714.
107. Blache, D.; Rustan, I.; Durand, P.; Lesgards, G.; Loreau, N. Gas chromatographic analysis of resveratrol in plasma, lipoproteins and cells after in vitro incubations. J. Chromatogr. B 1997, 702, 103-110.
108. Biasutto, L.; Marotta, E.; Garbisa, S.; Zoratti, M.; Paradisi, C. Determination of quercetin and resveratrol in whole blood-implications for bioavailability studies. Molecules 2010, 15, 6570-6579.
109. Andres-Lacueva, C.; Macarulla, M.T.; Rotches-Ribalta, M.; Boto-Ordonez, M.; Urpi-Sarda, M.; Rodriguez, V.M.; Portillo, M.P. Distribution of resveratrol metabolites in liver, adipose tissue, and skeletal muscle in rats fed different doses of this polyphenol. J. Agric. Food Chem. 2012, 60, 4833-4840.
110. Patel, K.R.; Brown, V.A.; Jones, D.J.; Britton, R.G.; Hemingway, D.; Miller, A.S.; West, K.P.; Booth, T.D.; Perloff, M.; Crowell, J.A.; et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70, 7392-7399.
111. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R.H.; van de Weijer, T.; Goossens, G.H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S.; et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14, 612-622.
112. Nunes, T.; Almeida, L.; Rocha, J.F.; Falcao, A.; Fernandes-Lopes, C.; Loureiro, A.I.; Wright, L.; Vaz-da-Silva, M.; Soares-da-Silva, P. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J. Clin. Pharmacol. 2009, 49, 1477-1482.